Profin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Profin

Quick Facts

Property Description
Active ingredient Finasteride (INN)
Form Oral Tablet
Pharmacological class 5-Alpha Reductase Inhibitor
Origin Synthetic compound (4-Azasteroid)
Target Mechanism Inhibits conversion of Testosterone to DHT

What Type of Drug is Profin (Finasteride)?

Profin is a specific brand of systemic, prescription-only medication administered as an oral tablet for adult male patients. Its active component is Finasteride, an International Nonproprietary Name (INN) compound that is widely recognized in clinical practice. The drug is classified as a 5-Alpha Reductase Inhibitor. This classification distinguishes it as a targeted enzyme blocker, which operates by interfering with a specific hormonal conversion process. As a monotherapy containing only Finasteride, Profin is positioned as a standard pharmaceutical treatment for conditions related to androgen excess.

Composition, Form, and Synthetic Origin

Finasteride is a highly specialized synthetic 4-Azasteroid compound derived from chemical synthesis. This compound's unique structure allows it to selectively inhibit the 5alpha-Reductase enzyme. The specific formulation of Profin is an oral tablet, which is the standardized dosage form for Finasteride when systemic action is required. This oral route of administration ensures the active agent is distributed throughout the body to reach the enzyme in target tissues.

The General Therapeutic Action of Profin

The primary function of Profin is to modulate androgen-dependent physiological processes. It achieves this by inhibiting the action of the 5alpha-Reductase enzyme, thereby obstructing the biological conversion of the androgen testosterone into the potent metabolite, Dihydrotestosterone (DHT). This mechanism is clinically recognized for its ability to significantly lower circulating and tissue-specific DHT levels. The overarching therapeutic purpose of the drug is, therefore, to address physiological states that are directly driven by excessive DHT activity, such as maintaining prostate health or slowing hair follicular changes.

Regulatory References

  1. NIH, StatPearls

What side effects are possible with Profin?

Possible Side Effects and Safety Information

The official safety profile of Profin (Finasteride) is structured by government regulatory agencies through classifications derived from clinical trials and post-marketing surveillance. Adverse reactions are grouped by frequency and physiological system involved.

Adverse Reactions Classified by Frequency

Adverse reactions that are frequently observed, or Common (affecting up to 1 in 10 patients), primarily involve the Reproductive System and Breast Disorders. These include decreased libido, erectile dysfunction, and ejaculation disorders (including decreased volume of ejaculate).

Reactions classified as Uncommon (affecting up to 1 in 100 patients) include breast tenderness and enlargement (gynecomastia) and rash.

Side effects reported during post-marketing experience, for which the frequency is Not Known (cannot be estimated from available data), include depression, suicidal ideation, palpitation, testicular pain, and specific hypersensitivity reactions like angioedema. Additionally, reports of sexual dysfunction and depressed mood persisting after discontinuation of treatment have been documented.

Serious Adverse Reactions and Safety Considerations

Serious Adverse Reactions documented in regulatory safety labels include reports of Male Breast Cancer and an associated risk of developing High-Grade Prostate Cancer with 5alpha-reductase inhibitors.

Time-related patterns indicate that sexual adverse effects are often most frequent at the start of treatment and may resolve with continued use. However, the potential for persistent sexual dysfunction after cessation is noted in regulatory documents.

Specific Safety Constraints include the medication being formally contraindicated for women who are or may be pregnant due to the risk of fetal external genitalia abnormalities. Furthermore, the drug causes a significant decrease in serum Prostate Specific Antigen (PSA) levels, which must be accounted for when interpreting laboratory results.

Overdose and Emergency Response

The official regulatory profile for Profin (Finasteride) overdose is characterized by the absence of documented acute toxicity at doses substantially higher than the typical prescribed amount. Regulatory documents, including those from the FDA and EMA, state that clinical trials involving single doses of up to 400 mg and multiple daily doses up to 80 mg for three months did not result in adverse effects or dose-related side effects. This means no specific overdose manifestations—such as characteristic clinical signs, symptoms, or physiological changes—have been formally listed in the prescribing information based on this high-exposure data.

Despite the absence of documented toxicity at these high levels, taking more than the prescribed amount requires the user to seek immediate medical attention. This action is mandated because no specific treatment or antidote is known or recommended by regulatory authorities for Finasteride overdose. In the event a suspected overdose occurs, the official management is entirely symptomatic and supportive. This regulatory guidance is constrained by the lack of a specific antagonist, leading to the requirement for professional care and general observation, consistent with standard clinical practice for drug over-ingestion where a known antidote is unavailable. The regulatory documents do not specify any unique population-specific considerations regarding overdose severity.

Therapeutic Uses of Profin

Profin: Main Uses and Therapeutic Benefits

Profin (Finasteride) is commonly used in situations involving certain distressing symptoms related to conditions presenting with systemic or localized discomfort in adult males, which may help ease the overall symptom burden. This medication is applied across domains where additional symptomatic support is needed, specifically for conditions linked to organ-specific functional stress.

Profin is considered relevant for managing symptom clusters that may become intense or disruptive across conditions presenting with localized discomfort, such as Benign Prostatic Hyperplasia (BPH) and Male Pattern Hair Loss (Androgenetic Alopecia).

In the context of BPH, the medication is applied in clinical settings to help with symptoms that interfere with daily functioning, such as a weak urinary stream, frequent urination, and difficulty emptying the bladder completely. The primary therapeutic benefit for BPH contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability in clinical settings.

For hair loss, the primary therapeutic benefit offers symptomatic relief that helps patients cope more steadily with symptom fluctuations by slowing down or halting further hair loss, which supports the management of progressive thinning and loss of scalp hair.

“Profin is commonly used to help with the progressive thinning and loss of scalp hair and is applied in clinical settings that involve increased discomfort or tension related to BPH.”

Quick Fact: Relief for BPH Quick Fact: Relief for Hair Loss
Symptom Focus: Lower Urinary Tract Symptoms (LUTS) Symptom Focus: Progressive scalp hair thinning
Primary Benefit: Assists with maintaining functional stability through the relief of bothersome urinary symptoms. Primary Benefit: Supports the management of progressive thinning and loss of scalp hair.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Profin (Finasteride) is regulated for use exclusively by adult men and is not indicated for use in any female or pediatric population. The official labeling defines several strict exclusions regarding eligibility.

Contraindicated Populations

  • Women: The medicine is contraindicated in all females, particularly those who are or may be pregnant, due to the established potential to cause abnormalities of the external genitalia in a male fetus.
  • Pediatric Patients: Use is not indicated for the pediatric population (under 18 years) as safety and efficacy have not been established.
  • Allergy: Individuals with a known hypersensitivity to Finasteride or any excipients in the formulation are prohibited from use.

Condition-Specific Eligibility

Regulatory documents advise caution when administering Profin to patients with liver function abnormalities, as the drug is extensively metabolized in the liver. However, no dosage adjustment is necessary for older adults (geriatric use) or for patients with renal impairment. The medicine is also prohibited for patients with certain hereditary metabolic disorders (such as total lactase deficiency) due to the presence of tablet excipients. Additionally, pregnant women must not handle crushed or broken tablets due to the potential for absorption.

What should I know about interactions with other medicines?

Profin Interactions with Other Medicines and Products

Official regulatory information for Profin establishes interaction constraints primarily across pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms.

Interaction scope

Classification Interacting Agents/Classes
Contraindicated Monoamine Oxidase Inhibitors (MAOIs), including isocarboxazid, phenelzine, and procarbazine.
Significant PK CYP Enzyme Inhibitors: Strong and moderate inhibitors of CYP2C9 and CYP3A4 may increase Profin exposure.
Significant PD Other nonsteroidal anti-inflammatory drugs (NSAIDs) and antiplatelet agents.

Resulting interaction structure

Official regulatory statements advise that co-administration with MAOIs is strictly forbidden, requiring a separation of at least 14 days due to the risk of hypertensive crisis.

Concomitant use with other NSAIDs or antiplatelet agents is restricted due to a heightened PD risk of gastrointestinal bleeding. Monitoring for changes in systemic exposure is necessary when Profin is combined with certain anticoagulants (e.g., warfarin) or agents with a narrow therapeutic index, such as lithium, methotrexate, or cyclosporine, as Profin may alter their clearance, leading to increased levels.

Additionally, the consumption of alcohol is identified in official documents as an exposure-modifying substance that may increase the risk of serious gastrointestinal events when combined with Profin.

Mechanism of Action

How Profin Works

Profin's action is defined by its selective mechanism that modifies a core pathway in androgen metabolism. It operates entirely on a biochemical level to modify downstream hormonal signaling.


Targeted Inhibition of the 5-Alpha Reductase Enzyme

This domain covers the drug's molecular interaction with its primary biological target. Profin acts as a specific and functionally irreversible competitive inhibitor of the 5-Alpha Reductase (5alpha-R) Type II isoenzyme. This targeted deactivation establishes the molecular basis for the drug's systemic action by inhibiting the enzymatic catalyst within the metabolic process.


Attenuation of High-Affinity Androgen Signaling

The inhibition of the 5alpha-R enzyme blocks the conversion of Testosterone into Dihydrotestosterone (DHT), an androgen with higher receptor affinity. This leads to a rapid and sustained decrease in local tissue and circulating DHT concentrations, thereby reducing the stimulus that DHT exerts on Androgen Receptors in sensitive cells. The resulting physiological effect is the attenuation of cellular activity that is driven by DHT signaling.


Constraints of the Molecular-to-Physiological Cascade

This domain explains the time-dependent nature and limitations of the mechanism. While the molecular enzyme binding is fast, the full physiological effect is constrained by the slow turnover of the affected cell populations, requiring a prolonged duration for the physiological effect to fully manifest. Furthermore, the drug's mechanism does not affect the Type I 5alpha-R isoenzyme, representing a permanent mechanistic constraint that prevents absolute DHT suppression.

Dosage and Administration Information

Profin is a systemic prescription medicine administered via the oral route as a film-coated tablet, following a once-daily schedule. The official dosing regimen is strictly tied to the approved clinical use, establishing two separate, standard daily doses. For the management of Benign Prostatic Hyperplasia (BPH), the required regimen is one 5 mg tablet once daily. In contrast, the use for Male Pattern Hair Loss follows a lower strength, requiring one 1 mg tablet once daily.

The medication may be administered with or without meals, and the tablet must always be swallowed whole; it is officially stated that the tablet must not be crushed, broken, or chewed. To maintain consistent systemic levels, it is recommended to take the dose at approximately the same time each day. In the event a dose is missed, official instructions specify to skip the missed dose and resume the regular schedule with the next tablet, rather than doubling up.

Profin is authorized for long-term, continuous therapy. For the hair loss regimen, uninterrupted daily use for at least three to six months is typically required before the therapeutic stabilization is achieved. It is an established principle of use that the cessation of treatment will result in a reversal of the effect within several months. Furthermore, official clinical parameters indicate that no dosage adjustment is necessary for older adults or for patients with renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Profin


Evidence for use in Benign Prostatic Hyperplasia (BPH)

The clinical evaluation of Profin for Benign Prostatic Hyperplasia (BPH) primarily comes from large-scale, long-term Randomized Controlled Trials (RCTs). These studies typically compare Profin to an inactive substance (placebo) or to other established treatments. The research was conducted on adult men typically aged 45 and older who were experiencing moderate to severe symptoms of BPH, particularly those with a clinically enlarged prostate. Results apply only to these populations.

Researchers in these trials focused on several outcomes reflecting daily functioning or activity level. These included how symptoms were measured to evolve in the observed populations, using standardized scoring systems to track Lower Urinary Tract Symptoms (LUTS). Studies also monitored objective functional measures, such as how quickly urine flows, and tracked changes in the size of the prostate gland. Long-term findings describe patterns observed in the studies, showing how symptom scores and functional measures were recorded to evolve in the observed populations over time.

Evidence for use in Male Pattern Hair Loss (Androgenetic Alopecia)

The research base exploring Profin for Male Pattern Hair Loss consists mainly of short- to intermediate-term (1-2 year) placebo-controlled RCTs. These studies were generally conducted on adult men between the ages of 18 and 60 who had mild to moderate, ongoing hair loss on the top and crown of the scalp. The research focused on outcomes monitoring physiological strain or stress related to hair thinning.

Research examined short-term changes; trials reported differences in mean objective hair counts in the defined scalp area for participants receiving Profin compared to those receiving placebo during the primary study period. Furthermore, the studies monitored if the initial observations of hair count changes were sustained with continued use over several years, often through non-randomized, open-label extension studies.

What is Still Uncertain in the Research Landscape

While a substantial body of evidence exists, the research highlights what is known and what is still uncertain. One key limitation is that long-term effects are not fully established across all possible outcomes. Evidence quality varies across studies, and data for certain groups, such as those with certain comorbidities, remain insufficient. The results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly. Comparative evidence that directly contrasts Profin against all other treatments for BPH or hair loss in large, head-to-head trials is limited in scope.

Key Studies & References

  1. Finasteride Treatment for Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis
  2. Finasteride: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Profin (FAQ)

Q: How quickly does Profin start working after the first dose?

A: Official information indicates that the medicine's molecular action begins rapidly after administration, affecting hormonal levels. However, the full physical benefit on the target condition takes a prolonged duration to become evident due to the slow turnover of the affected cells. For instance, studies suggest it may take three to six months of continuous use before therapeutic stabilization is achieved for Male Pattern Hair Loss.


Q: Why do some people experience stomach upset with Profin?

A: General stomach upset is not frequently listed as a common or uncommon side effect when Profin is used on its own. However, official safety documents state that combining the medicine with alcohol or with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of experiencing serious gastrointestinal events.


Q: How long do I need to take Profin before seeing the full benefit?

A: For Benign Prostatic Hyperplasia (BPH), clinical observations indicate it can typically take up to six months of continuous treatment for the full effects to be observed. For Male Pattern Hair Loss, studies indicate that at least three to six months of uninterrupted daily use were typically needed before therapeutic changes, such as stabilization of hair count, were achieved.


Q: Is the Profin tablet supposed to be split or chewed?

A: Regulatory instructions clearly state that the tablet must always be swallowed whole and should never be crushed, broken, or chewed. This constraint is due to concerns about the potential absorption of the active ingredient if the tablet coating is compromised, which is particularly noted as a consideration for pregnant women who might handle the broken tablets.


Q: Why is Profin not approved for everyone with the condition?

A: The medicine is strictly indicated only for adult men and is not approved for use in any female or pediatric population. Official information explains that the clinical evidence base applies only to the populations studied in the research. Therefore, its suitability for all individuals, particularly those with certain health factors, has not been officially established.


Q: Can Profin be used in combination with other prescription drugs?

A: Official documentation lists several drugs or drug classes that are contraindicated (must not be used) or require specific monitoring due to potential drug interactions, such as Monoamine Oxidase Inhibitors (MAOIs). Regulatory documents describe the known interactions, and consulting a healthcare professional is the standard approach for managing potential constraints with any prescription drug.


Q: What defines a 'serious' side effect of Profin?

A: Serious adverse reactions documented in regulatory safety labels include reports of Male Breast Cancer and an associated risk of developing high-grade prostate cancer as observed with this class of drug. Post-marketing surveillance has also noted reports of suicidal ideation.


Q: What is the difference between Profin and other similar medications?

A: Profin (Finasteride) is classified as a 5-Alpha Reductase Inhibitor. This class of medication works by blocking an enzyme that converts testosterone into Dihydrotestosterone (DHT). Profin specifically and selectively targets the Type II isoenzyme of 5-Alpha Reductase, which defines its molecular action compared to other similar medications that might inhibit both Type I and Type II isoenzymes.


Q: Is Profin considered a 'strong' medicine?

A: Profin is a prescription-only medicine that acts as a specific and functionally irreversible competitive inhibitor of its target enzyme, 5-Alpha Reductase Type II. This action leads to a rapid and sustained decrease in the potent androgen, Dihydrotestosterone (DHT), which defines its known biochemical impact.


Q: Can Profin cause changes in mood or personality?

A: The official safety profile includes reports of mood disturbances. Specifically, reports of depression and suicidal ideation have been documented in post-marketing surveillance. The frequency of these reactions cannot be definitively estimated from the available data.


Q: Does Profin interact with birth control pills?

A: Official regulatory documents do not list oral contraceptives as a specific drug interaction. However, the medicine is contraindicated (not allowed) for use in women, particularly those who are or may be pregnant, because of the risk of harm to a male fetus.


Q: Is Profin a controlled substance?

A: Profin (Finasteride) is classified as a prescription-only medicine by major regulatory bodies. It is not listed as a controlled substance that is subject to special governmental restrictions on dispensing and refills.


Q: How does Profin impact blood pressure?

A: High blood pressure is not listed in the official safety data as a common or uncommon adverse reaction. However, some regulatory sources mention that low blood pressure (hypotension) is a potential rare effect, particularly when Profin is administered alongside alpha-blockers for treating Benign Prostatic Hyperplasia (BPH).


Q: Can Profin cause problems with the liver?

A: Official documents advise caution when administering Profin to patients with existing liver function abnormalities because the drug is extensively processed (metabolized) in the liver. Although elevations in liver enzymes were reported in clinical trials, these effects were typically temporary and similar to those seen with a placebo.


Q: Is Profin available as a generic medicine?

A: Yes, the active ingredient in Profin is Finasteride, which is the official nonproprietary name. Generic versions of Finasteride are available and have been approved by regulatory agencies for use.


Q: Does Profin carry a specific warning in its official documentation?

A: Yes, official documentation includes specific warnings. These warnings highlight the potential increased risk of high-grade prostate cancer, the required adjustment for interpreting Prostate Specific Antigen (PSA) blood test results, and the risk to a male fetus if a pregnant woman absorbs the drug.


Q: Is it safe to drink alcohol in moderation while using Profin?

A: Official regulatory statements identify alcohol as an exposure-modifying substance. When combined with Profin, alcohol may increase the risk of serious gastrointestinal events. The potential risk associated with alcohol consumption is documented in official regulatory statements.


Q: Can Profin be used for stress or anxiety?

A: The medicine is indicated only for the treatment of specific medical conditions: Benign Prostatic Hyperplasia (BPH) and Male Pattern Hair Loss. Use for stress, anxiety, or any other condition is not an approved therapeutic purpose listed in official labeling.


Q: Does Profin lose effectiveness over time?

A: Clinical trials for both approved indications were conducted for several years. The research indicated that the observed effects on symptoms and hair counts were generally sustained with continued, long-term use, suggesting the medicine's effectiveness is maintained.


Q: What is the typical age range for people taking Profin?

A: The medicine is officially indicated only for adult men. Clinical studies included men generally aged 18 to 60 for Male Pattern Hair Loss, and primarily men aged 45 and older for Benign Prostatic Hyperplasia. The use of Profin is not approved for the pediatric population (under 18 years).

How should Profin be stored and disposed of?

Storage Requirements

Profin tablets must be stored at room temperature, typically defined as 15 C to 30 C (59 F to 86 F). The medicine must be kept in its original container and the container should be kept tightly closed to protect the tablets from moisture and excess heat, as per official labeling. The medicine must be stored out of the sight and reach of children to prevent accidental exposure.

Handling and Disposal

A critical handling requirement is that women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets, as the active ingredient can be absorbed. The tablets are coated to prevent contact with the drug during normal handling.

Disposal of unused or outdated Profin must be performed in accordance with local regulatory requirements. Medicines should not be thrown into household waste or poured down the sink unless specifically instructed by the label, as proper disposal is necessary to manage pharmaceutical waste. Consult a healthcare professional for guidance on disposal methods, such as drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Profin found in:

A-Z Index: